Comprehensive computational strategies for multi-target drug discovery in inflammatory bowel disease utilizing bioactive compounds
Abstract Inflammatory bowel disease (IBD) is a chronic gastrointestinal condition that encompasses ulcerative colitis (UC) and Crohn’s disease (CD). Targeting both inflammation and the epithelial barrier simultaneously can significantly improve symptom management in IBD, as a promising strategy. In...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-05-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-98771-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850042412159729664 |
|---|---|
| author | Pardis Mansouri Pegah Mansouri Sohrab Najafipour Seyed Amin Kouhpayeh Akbar Farjadfar Esmaeil Behmard |
| author_facet | Pardis Mansouri Pegah Mansouri Sohrab Najafipour Seyed Amin Kouhpayeh Akbar Farjadfar Esmaeil Behmard |
| author_sort | Pardis Mansouri |
| collection | DOAJ |
| description | Abstract Inflammatory bowel disease (IBD) is a chronic gastrointestinal condition that encompasses ulcerative colitis (UC) and Crohn’s disease (CD). Targeting both inflammation and the epithelial barrier simultaneously can significantly improve symptom management in IBD, as a promising strategy. In this study, we focused on addressing both inflammation and the epithelial barrier. Until now, each therapeutic target including phosphodiesterase 4 (PDE4) and prolyl hydroxylase domain enzymes 1 and 2 (PHD1/2) have been studied separately. PDE4 plays a key role in the inflammatory process by converting cyclic AMP (cAMP) to AMP and its inhibition can suppress the production of inflammatory cytokines. Research has shown that inhibiting PHD1 and PHD2 increases levels of hypoxia-inducible factor-alpha (HIF-α), which in turn strengthens the epithelial barrier by promoting the expression of protective factors such as mucins and β-defensins. Through virtual screening, molecular docking, and molecular dynamics simulations, we identified five compounds—Cassiamin C, Ginkgetin, Hinokiflavone, Sciadopitysin, and Sojagol—as promising new drug candidates for IBD treatment. All compounds demonstrated superior free binding energy for the three targets compared to reference ligands, except Sojagol concerning PDE4B. Among these compounds, Ginkgetin was the best compound with potential ability of targeting multiple drug target proteins. Future experimental studies are warranted to validate these findings. |
| format | Article |
| id | doaj-art-0da4eb8b7d5c41a585f858937293000b |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-0da4eb8b7d5c41a585f858937293000b2025-08-20T02:55:35ZengNature PortfolioScientific Reports2045-23222025-05-0115111610.1038/s41598-025-98771-wComprehensive computational strategies for multi-target drug discovery in inflammatory bowel disease utilizing bioactive compoundsPardis Mansouri0Pegah Mansouri1Sohrab Najafipour2Seyed Amin Kouhpayeh3Akbar Farjadfar4Esmaeil Behmard5Student Research Committee, Fasa University of Medical SciencesStudent Research Committee, Fasa University of Medical SciencesSchool of Advanced Technologies in Medicine, Fasa University of Medical SciencesDepartment of Pharmacology, Faculty of Medicine, Fasa University of Medical SciencesDepartment of Medical Biotechnology, Fasa University of Medical SciencesSchool of Advanced Technologies in Medicine, Fasa University of Medical SciencesAbstract Inflammatory bowel disease (IBD) is a chronic gastrointestinal condition that encompasses ulcerative colitis (UC) and Crohn’s disease (CD). Targeting both inflammation and the epithelial barrier simultaneously can significantly improve symptom management in IBD, as a promising strategy. In this study, we focused on addressing both inflammation and the epithelial barrier. Until now, each therapeutic target including phosphodiesterase 4 (PDE4) and prolyl hydroxylase domain enzymes 1 and 2 (PHD1/2) have been studied separately. PDE4 plays a key role in the inflammatory process by converting cyclic AMP (cAMP) to AMP and its inhibition can suppress the production of inflammatory cytokines. Research has shown that inhibiting PHD1 and PHD2 increases levels of hypoxia-inducible factor-alpha (HIF-α), which in turn strengthens the epithelial barrier by promoting the expression of protective factors such as mucins and β-defensins. Through virtual screening, molecular docking, and molecular dynamics simulations, we identified five compounds—Cassiamin C, Ginkgetin, Hinokiflavone, Sciadopitysin, and Sojagol—as promising new drug candidates for IBD treatment. All compounds demonstrated superior free binding energy for the three targets compared to reference ligands, except Sojagol concerning PDE4B. Among these compounds, Ginkgetin was the best compound with potential ability of targeting multiple drug target proteins. Future experimental studies are warranted to validate these findings.https://doi.org/10.1038/s41598-025-98771-wInflammatory bowel diseaseMD simulationBioactive compoundsGinkgetinMulti-target drugs |
| spellingShingle | Pardis Mansouri Pegah Mansouri Sohrab Najafipour Seyed Amin Kouhpayeh Akbar Farjadfar Esmaeil Behmard Comprehensive computational strategies for multi-target drug discovery in inflammatory bowel disease utilizing bioactive compounds Scientific Reports Inflammatory bowel disease MD simulation Bioactive compounds Ginkgetin Multi-target drugs |
| title | Comprehensive computational strategies for multi-target drug discovery in inflammatory bowel disease utilizing bioactive compounds |
| title_full | Comprehensive computational strategies for multi-target drug discovery in inflammatory bowel disease utilizing bioactive compounds |
| title_fullStr | Comprehensive computational strategies for multi-target drug discovery in inflammatory bowel disease utilizing bioactive compounds |
| title_full_unstemmed | Comprehensive computational strategies for multi-target drug discovery in inflammatory bowel disease utilizing bioactive compounds |
| title_short | Comprehensive computational strategies for multi-target drug discovery in inflammatory bowel disease utilizing bioactive compounds |
| title_sort | comprehensive computational strategies for multi target drug discovery in inflammatory bowel disease utilizing bioactive compounds |
| topic | Inflammatory bowel disease MD simulation Bioactive compounds Ginkgetin Multi-target drugs |
| url | https://doi.org/10.1038/s41598-025-98771-w |
| work_keys_str_mv | AT pardismansouri comprehensivecomputationalstrategiesformultitargetdrugdiscoveryininflammatoryboweldiseaseutilizingbioactivecompounds AT pegahmansouri comprehensivecomputationalstrategiesformultitargetdrugdiscoveryininflammatoryboweldiseaseutilizingbioactivecompounds AT sohrabnajafipour comprehensivecomputationalstrategiesformultitargetdrugdiscoveryininflammatoryboweldiseaseutilizingbioactivecompounds AT seyedaminkouhpayeh comprehensivecomputationalstrategiesformultitargetdrugdiscoveryininflammatoryboweldiseaseutilizingbioactivecompounds AT akbarfarjadfar comprehensivecomputationalstrategiesformultitargetdrugdiscoveryininflammatoryboweldiseaseutilizingbioactivecompounds AT esmaeilbehmard comprehensivecomputationalstrategiesformultitargetdrugdiscoveryininflammatoryboweldiseaseutilizingbioactivecompounds |